PYXS stock Statistics — Pyxis Oncology, Inc. filings, insiders & smart money

Price and daily changeSign in

Earnings2 Nov 2026

52-week rangeSign inDay rangeSign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-08-12 · filed common shares: 83.40M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.82%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 4.76%
Short ratioDays to cover, as published by FINRA: 6.96
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 46.00%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 55.50%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross marginFY Dec 25: 82.77%
Operating marginFY Dec 25: -609.18%
Net margin: —
EBITDA marginFY Dec 25: -576.63%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -179.10%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -99.62%

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-1.40

EPS (fwd)

Cash & equivalentsas of Jun 26: $18.85M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $17.83M
Debt / equityas of Jun 26: 155.87%
Current ratioas of Jun 26: 1.34
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Jun 25: 5.20
Operating cash flowTTM to Jun 26: -$67.91M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$67.91M
TTM revenue / diluted share: —